Table 1.
Patient demographics and baseline characteristics
| Variable | Full (n = 376) |
ERC (n = 174) |
AVD (n = 55) |
NVD (n = 147) |
|---|---|---|---|---|
| Age, Mean (SD; yrs) | 69.5 (13.2) | 69.0 (13.2) | 71.8 (13.1) | 69.3 (13.4) |
| Male, n (%) | 185 (49.2%) | 84 (48.3%) | 30 (54.5%) | 71 (48.3%) |
| Hispanic, n (%) | 42 (11.2%) | 27 (15.5%) | 4 (7.3%) | 11 (7.5%) |
| Race, n (%) | ||||
| Caucasian | 243 (64.6%) | 113 (64.9%) | 35 (63.6%) | 95 (64.6%) |
| African American | 75 (19.9%) | 34 (19.5%) | 10 (18.2%) | 31 (21.1%) |
| Asian American | 1 (0.3%) | 0 (0%) | 0 (0%) | 1 (0.7%) |
| Native American | 1 (0.3%) | 0 (0%) | 1 (1.8%) | 0 (0%) |
| Other | 27 (7.2%) | 19 (10.9%) | 2 (3.6%) | 6 (4.1%) |
| Not Available | 29 (7.7%) | 8 (4.6%) | 7 (12.7%) | 14 (9.5%) |
| BMI, Mean (SD; kg/m2) | 32.8 (15.2) | 34.2 (20.7) | 29.4 (7.2) | 32.4 (7.6) |
| Primary Insurance Status, n (%) | ||||
| Commercial | 104 (27.7%) | 47 (27.0%) | 16 (29.1%) | 41 (27.9%) |
| Medicare | 235 (62.5%) | 103 (59.2%) | 36 (65.5%) | 96 (65.3%) |
| Medicaid | 20 (5.3%) | 11 (6.3%) | 3 (5.5%) | 6 (4.1%) |
| Tricare/Other Military or VA | 4 (1.1%) | 2 (1.1%) | 0 (0.0%) | 2 (1.4%) |
| Uninsured | 1 (0.3%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) |
| Other | 8 (2.1%) | 7 (4.0%) | 0 (0.0%) | 1 (0.7%) |
| Unknown | 4 (1.1%) | 3 (1.7%) | 0 (0.0%) | 1 (0.7%) |
| Primary Cause of CKD, na (%) | ||||
| Known cause | n = 113 | n = 69 | n = 13 | n = 31 |
| Diabetes | 44 (38.9%) | 30 (43.5%) | 2 (15.4%) | 12 (38.7%) |
| Hypertension | 64 (55.6%) | 36 (52.2%) | 11 (84.6%) | 17 (54.8%) |
| Other | 5 (4.4%) | 3 (4.3%) | 0 (0.0%) | 2 (6.5%) |
| CKD Stage, n (%) | ||||
| CKD Stage 3 | 204 (54.3%) | 81 (46.6%) | 21 (38.2%) | 102 (69.4%) |
| CKD Stage 4 | 172 (45.7%) | 93 (53.4%) | 34 (61.8%) | 45 (30.6%) |
| Comorbidities, n (%) | ||||
| Diabetes | 194 (51.6%) | 90 (51.7%) | 29 (52.7%) | 75 (51.0%) |
| Hypertension | 303 (80.6%) | 128 (73.6%) | 46 (83.6%) | 129 (87.8%) |
| Anemia | 151 (40.2%) | 67 (38.5%) | 23 (41.8%) | 61 (41.5%) |
| Heart Failure | 48 (12.6%) | 14 (8.0%) | 10 (18.2%) | 24 (16.3%) |
| Coronary artery disease | 42 (11.2%) | 17 (9.8%) | 5 (9.1%) | 20 (13.6%) |
| Angina | 3 (0.8%) | 1 (0.6%) | 1 (1.8%) | 1 (0.7%) |
| Peripheral vascular disease | 7 (1.9%) | 3 (1.7%) | 1 (1.8%) | 3 (2.0%) |
| Cerebral vascular disease | 4 (1.1%) | 3 (1.7%) | 1 (1.8%) | 0 (0.0%) |
| Cancer | 4 (1.1%) | 3 (1.7%) | 0 (0.0%) | 1 (0.7%) |
| Hyperlipidemia | 132 (35.1%) | 48 (27.6%) | 16 (29.1%) | 68 (46.3%) |
| None | 50 (13.3%) | 39 (22.4%) | 4 (7.3%) | 7 (4.8%) |
| Concomitant Medications, n (%) | ||||
| Phosphate Binders | 14 (3.7%) | 6 (3.4%) | 3 (5.5%) | 5 (3.4%) |
| Anemia Medications | 71 (18.9%) | 25 (14.4%) | 15 (27.3%) | 31 (21.1%) |
ERC extended-release calcifediol; AVD active vitamin D analog; NVD nutritional vitamin D; BMI body mass index; CKD chronic kidney disease
aamong those with a known cause